DRDATSONS

Dr. Datson's Labs Limited has informed the Exchange that due to non-availability of requisite quorum the scheduled Meeting of the Board of Directors of the Company to be held on March 15, 2014, could not be held and it is decided to the said board meeting to be held the day and date of which will be to the exchange separately.

Dr. Datson's Labs Limited has informed the Exchange that Dr. Ullooppee Badade and Mr. Balkrishna Parab, Directors of the Company, has tendered their resignation from the Directorship of the company with effect from February 24, 2014.Further, Mr. Prabhat Kumar Goyal, Executive-Whole time Director of the company vacated the post as the Executive Director but will continue as an Non Executive Non Independent Director of the company with effect from February 24, 2014.

Dr. Datson's Labs Limited has submitted to the exchange the standalone financial results for the period ended 31-Dec-2013.

Dr. Datson's Labs Limited has submitted to the Exchange, vide letter dated February 04, 2014 a copy of Disclosures under Regulation 13(4), 13(4A) and 13(6) of Prohibition of Insider Trading Regulation, 1992.

Shree Dhoot Trading & Agencies Ltd, Dome-Bell Electronics India Pvt Ltd, Evans Fraser & Co India Ltd & Nippon Investment & Finance Co. Pvt Ltd has submitted to the Exchange vide letter dated January 29, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated January 230, 2014 a copy of Disclosure under Regulation 13(1), 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has submitted to the Exchange, vide letter dated January 29, 2014 a copy of Disclosures under Reaulatlon 13(6) of Prohibition of Insider Trading Regulation, 1992.

Shree Dhoot Trading And Agencies Limited has submitted to the Exchange vide letter dated January 28, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Religare Finvest Limited has submitted to the Exchange, vide letter dated January 28, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated January 29, 2014 a copy of Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated January 28, 2014 a copy of Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Bakulesh T Shah has submitted to the Exchange vide letter dated January 27, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated January 27, 2014 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has submitted to the exchange the standalone financial results for the period ended 30-sep-2013.

Dr. Datson's Labs Limited has informed the Exchange regarding the outcome of the Annual General Meeting of the Company held on September 30, 2013.

Price movement : Significant price movement has been observed in Dr. Datson's Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Dr. Datson's Labs Limited has vide its letter inter-alia stated, "The Company is in the process of exploring various strategic moves by formulating policies and by entering into various agreements for the benefit of its shareholders and it is the policy of the Company to inform the stock exchang

Aanjaneya Lifecare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 30, 2013 :(1)To Issue 25,00,000 optionally convertible warrants on preferential basis to Promoter at a price as determined under the SEBI (ICDR) Regulations, 2009, as amended, subject to the approval members of the company.

Members of the Exchange are hereby informed that the name of Aanjaneya Lifecare Limited shall be changed to Dr. Datson s Labs Limited and the trading symbol of the Company be changed from AANJANEYA to DRDATSONS w.e.f. September 02, 2013.

Aanjaneya Lifecare Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended June 30,2013.

Aanjaneya Lifecare Limited has informed the Exchange that the Company has changed its name from AANJANEYA LIFECARE LIMITED TO "DR.DATSONS LABS LIMITED".

Aanjaneya Lifecare Limited has informed the Exchange regarding results of postal ballot as per clause 35A of listing agreement.

Aanjaneya Lifecare Ltd has informed the Exchange that: 1. Aanjaneya Lifecare Limited (ALL) became holding Company of "FAIR SUCCESS (H.K) LIMITED" a Company incorporated in the Hong Kong, by way of acquiring 100% ordinary share capital of the said Hong Kong based Company. 2. Aanjaneya Lifecare Limited (ALL) have incorporated Wholly owned Subsidiary named "Dr. Datsons Labs Limited" a Company incorporated in United Kingdom, by way of subscribing 100% ordinary share capital of the said Subsidiary Company.

Finaventure Capital Limited has submitted to the Exchange vide letter dated June 29, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Aanjaneya Lifecare Limited has informed the Exchange regarding outcome of the Board of Directors Meeting of the Company held on June 24, 2013.

Aanjaneya Lifecare Limited has submitted to the Exchange vide letter dated June 19, 2013 a copy of Disclosure under Regulation 13(4), 13(6) and 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Finaventure Capital Limited has submitted to the Exchange vide letter dated June 19, 2013 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, along with a copy of disclosure pursuant to Regulation 13(4) and 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Aanjaneya Lifecare Limited has submitted to the Exchange vide letter dated May 28, 2013 a copy of Disclosure under Regulation 13(4), 13(6) and 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Aanjaneya Lifecare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on June 17, 2013 has approved to reset the conversion price of Foreign Currency Convertible Bonds [FCCBs], subject to the approval of the Members of the Company.

Aanjaneya Lifecare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2013 decided to nominate Mr. Chandulal Champaklal Shah, as Chairman Emeritus. Mr. Chandulal Shah is an eminent social worker and was awarded Dalit Mitra Puraskar and he is also Special Executive Officer of Government of Maharashtra. He has over 35 years experience in business. He will not be a board member of the company.

Aanjaneya Lifecare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2013 has recommended a dividend, subject to the approval of shareholders in the ensuing Annual General Meeting of the Company @ 1.00% on 1,38,87,151 Equity Shares of the Rs.10/- each (i.e. Rs. 0.10/- (Ten Paise) per Equity Share) to the concerned shareholders as on Record Date to be intimated in due course.

Aanjaneya Lifecare Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2013.

Finaventure Capital Ltd has submitted to the Exchange vide its letter dated May 28, 2013 a copy of Disclosure under Regulation 13(4), 13(6) and 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Finaventure Capital Ltd has submitted to the Exchange vide its letter dated May 02, 2013 a copy of Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Aanjaneya Lifecare Limited has informed the Exchange that Mr. Paul Chakkapan Naythatil Director of the Company, has tendered his resignation as an Independent Director of the company with effect from May 15, 2013.

Aanjaneya Lifecare Limited has submitted to the Exchange Vide its letter dated April 17, 2013 a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of (Prohibition of Insider Trading) Regulation, 1992.

Finaventure Capital Limited has submitted to the Exchange vide letter dated April 17, 2013 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011,along with a copy of disclosure pursuant to Regulation 13(4) and13(4A) of the SEBI (Prohibition of Insider Trading) Regulations, 1992..

Finaventure Capital Limited has submitted to the Exchange vide letter dated April 17, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Aanjaneya Lifecare Limited has submitted to the Exchange a copy of Disclosure under Regulation 13(4), 13(4A) and 13(6) of (Prohibition of Insider Trading) Regulation, 1992.

Aanjaneya Lifecare Limited has informed the Exchange that Mr. Kashi Vishwanathan, Chairman Emeritus of the Company, has tendered his resignation from the Chairman Emeritus of the company with effect from April 15, 2013.

Aanjaneya Lifecare Limited has submitted to the Exchange a copy of Disclosure, in respect of details of shares under Regulation 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Bakulesh T. Shah has submitted to the Exchange vide letter dated April 12, 2013 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Finaventure Capital Limited has submitted to the Exchange vide letter dated April 09, 2013 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011,along with a copy of disclosure pursuant to Regulation 13(4) and13(4A) of the SEBI (Prohibition of Insider Trading) Regulations, 1992..

Finaventure Capital Limited has submitted to the Exchange vide letter dated April 09, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Aanjaneya Lifecare Limited has submitted to the Exchange vide letter dated April 01, 2013 a copy of Disclosure under Regulation 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Finaventure Capital Ltd has submitted to the Exchange vide its letter dated April 01, 2013 a copy of disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(4) and13(4A) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Aanjaneya Lifecare Limited has informed the Exchange regarding closure of its FCCB Issue as on March 21, 2013. The said issue was opened for subscription on March 18, 2013. Further, as decided in the Meeting of the Board of Directors of the Company held on March 21, 2013, the Board of Directors has allotted 400 Bonds of US$100,000 each aggregating US$40 million.

Finaventure Capital Ltd has submitted to the Exchange vide its letter dated March 20, 2013 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Finaventure Capital Limited has submitted to the Exchange vide letter dated March 20, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Aanjaneya Lifecare Limited has submitted to the Exchange vide letter dated March 20, 2013 a copy of disclosure under Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Aanjaneya Lifecare Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on March 18, 2013 have decided that the date of opening of issuance of FCCB up to USD 75 million is on March 18, 2013.